FDA grants Opdivo combo Breakthrough Designation for melanoma

2nd August 2019 Uncategorised 0

Bempegaldesleukin, Nektar’s lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist.

More: FDA grants Opdivo combo Breakthrough Designation for melanoma
Source: News